-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
An integrated platform focusing on the investment and operation and management of the life science and technology industry - De Nuo Medical announced that it will join the cutting-edge medical fund Jishi Capital to form a joint venture in China with Metronom Health, an innovative blood glucose monitoring company in the United States.
The joint venture owns R&D in China Production and sales rights
.
This cooperation aims to accelerate the introduction of Metronom's innovative continuous glucose monitoring (CGM) product for diabetes into the Chinese market
.
The traditional finger blood test requires the patient to pierce the fingertip and test it 6-8 times a day.
The discrete blood glucose level is not only limited in information, but also painful causes poor patient compliance
.
Continuous blood glucose monitoring The blood glucose meter can provide continuous, comprehensive, and reliable blood glucose information around the clock through the micro sensor electrodes inserted under the skin, and send the data to smart devices and the cloud.
This helps patients and doctors understand the trend of blood glucose fluctuations and finds that it is not easy to be detected.
Metronom's CGM products have the world's leading and original photoenzyme glucose sensing technology, which has more excellent accuracy and reliable detection capabilities, especially in the low-sugar area, surpassing the detection range and measurement accuracy of traditional electrochemical reactions
.
Metronom products can be worn for up to 14 days and do not require regular fingertip calibration, which significantly reduces the patient's pain and risk of infection, and improves patient compliance
.
In addition, Memtronom's innovative CGM technology can speed up the digital management of diabetes, not only provide patients with diabetes-related science education, data analysis and other services, but also provide closed-loop services in conjunction with hospitals, enhance patient stickiness, and increase patients' willingness to pay
.
According to IDF statistics, China's diabetic patients reached 116 million in 2019, and it is expected to increase to 140 million in 2023.
The number of diabetic patients in China continues to be the largest in the world
.
At the same time, more than one-third of people in China have abnormal blood sugar and are in the pre-diabetes stage
.
Yiwei Zhao, co-founder and CEO of Denuo Medical, said: "Metronom has been deeply involved in diabetes management since its establishment, focusing on the development and production of diabetes CGM products
.
We look forward to working with Metronom for a long time to continue to help the company's R&D and product promotion, and to empower blood sugar management.
Step into the era of precision
Ms.
Shao Ying, founder of Jishi Capital, said: “The huge patient population provides a broad market potential for innovative diabetes monitoring technology.
Metronom CEO and President Olav Bergheim said: "We are very pleased to receive the strong support of JS Capital for our innovative CGM products.
Dano Capital has extensive experience in operation and management.
We are very optimistic about the cooperation with Dano and JS.
Cooperation
.
We are accelerating the search for CE certification and FDA approval, and are actively seeking approval for listing and sales in a market with huge potential like China
.
